The consortium is made up of 11 partners from 7 countries, representing industry, academia and patient advocacy groups. They are outstanding experts in preclinical and clinical ATMP therapies, clinical grade (GMP) manufacturing, genome editing, in depth-product specification, biomarker analyses for safety/efficacy profiling, advanced in vivo and in vitro model systems, and wide ranging communication with patients and their families.